The aim of the study was to evaluate the significance of unexplained elevated mater- nal serum alpha-fetoprotein in singleton pregnancies as a prediction of fetal risk. The inclusion criteria for patents with unexplained MSAFP elevations were a MSAFP level 2.0 or greater multiples of the median ( MoM ), a single gestation, a confirmed gestatio- nal age and no fetal malformation or death on ultrasonography. In this study, 991 woman who attended the antenatal clinic at Taejeon Eul Ji Hospital from March, 1996 to March, 1997 were reviewed and data from 79 women with elevated maternal serum alpha-fetoprotein levels were analysed. The 67 of 79 patients with elevated maternal serum alpha-fetoprotein levels had on unexplained elevated MSAFP level. 13 women could not follow up. 54 pregnant women with unexplained elevated MSAFP levels were classified as the index group of singleton pregn- ancy and were matched against a control group. 108 patients with MSAFP levels 0.5 to 2.0 MoM served as control group. The incidence of antepartum hemorrhage ( placental previa ), preterm labor, intrauterine growth retardation ( IUGR ), low birth weight and pregnancy induced hypertension ( PIH ) in two groups was analyzed and the results was subjected to Fisher's Exact Test. None of the patients in the index group had chromosomal abnormalites or birth defect. IUGR occurred in 7 ( 12.96% ) of the index group babies but in only 3 ( 2.78% ) in the control group ( p < 0.02 ). preterm labor occurred in 5 ( 9.26% ) in the index group compared with 2 ( 1.85% ) in the control group ( p < 0.05 ). low birth weight occurred in 3 ( 5.5% ) of the index group babies and in 1 ( 0.9% ) in the control group ( p < 0.1 ). This study suggests that patients with unexplained midtrimester elevations of MSAFP are increased risk for IUGR, preterm labor. But no significance differences were observed in the incidence of low birth weight, antepartum hemorrhage ( placental previa ), PIH.
alpha-Fetoproteins* ; Congenital Abnormalities ; Daejeon ; Female ; Fetal Growth Retardation ; Follow-Up Studies ; Gastroschisis ; Hemorrhage ; Humans ; Hypertension, Pregnancy-Induced ; Incidence ; Infant, Low Birth Weight ; Infant, Newborn ; Obstetric Labor, Premature ; Pregnancy Trimester, Second ; Pregnancy* ; Pregnant Women ; Ultrasonography

No abstract available.
Hypertension, Renovascular*

No abstract available.
Collagen

Alloys ; Bone Plates ; Cartilage ; Corrosion ; Diplopia ; Enophthalmos ; Fascia ; Glass ; Hope ; Humans ; Jaw Fixation Techniques ; Kidney ; Liver ; Lung ; Methylmethacrylate ; Orbit ; Polyethylene ; Polytetrafluoroethylene ; Silicones ; Spleen ; Titanium ; Wound Infection

No abstract available.
Transplants

No abstract available.
Appendicitis* ; Humans

No abstract available.
Helminths* ; Humans ; Jeollanam-do*

No abstract available.
Adenocarcinoma* ; Flow Cytometry*

This erratum is being published to correct of affiliation and add an acknowledgement.

The p53 gene is believed to play an important role through the mutation and overexpression in the progression of various human malignant tumors. The type IV collagenase (matrix metalloproteinase: MMP-2) initiates the degradation of the extracellular matrix, and consequently may play a role in the tumor invasion and metastasis. To investigate the correlation between clinicopathologic features of the colorectal adenocarcinomas and benign tumors and expression of p53 and MMP-2 proteins, we performed an immunohistochemical study on 40 colorectal adenocarcinomas, 20 adenomas and 20 hyperplastic polyps by using the antibodies to p53 and MMP-2 proteins. The positive expression rate of the p53 protein in adenocarcinomas was 62.5% and significantly higher than in benign tumors. The positive expression rate of the MMP-2 protein was 47.5% in adenocarcinomas, but there was no expression of MMP-2 protein in benign tumors. The difference in p53 and MMP-2 expression rates between malignant and non-malignant tumors was statistically significant. The positive expression rate of p53 protein in the non-metastatic and metastatic adenocarcinomas was 59.1 and 66.7%, respectively. The positive expression rate of MMP-2 protein in the non-metastatic and metastatic adencarcinomas was 45.5 and 50.0%, respectively. The correlation between several clinicopathologic features and expression of p53 and MMP-2 protein was not statistically significant, but the rate of positive MMP-2 immunoreactivity showed a statistically significant difference between Astler-Coller stage B1 C1 group and B2 C2 group of adenocarcinoma (p=0.0431). We concluded that the expression of p53 and MMP-2 protein contributes to the cancer development and MMP-2 may play a certain role in the invasiveness of the colorectal tumor. p53 and MMP-2 protein expression is not correlated with lymph node metastasis.
Adenocarcinoma* ; Adenoma ; Antibodies ; Collagenases ; Colorectal Neoplasms ; Extracellular Matrix ; Genes, p53 ; Humans ; Lymph Nodes ; Matrix Metalloproteinase 2* ; Neoplasm Metastasis ; Polyps